Background Between 2011 and 2013, global and national guidelines for preventing mother-
to-child transmission (PMTCT) of HIV shifted to recommend Option B+, the provision of …

Abstract In 2012, the World Health Organization recommended 'Option B+'(lifelong
antiretroviral treatment for HIV-infected pregnant women regardless of their CD4 count or …

Introduction In 2011, the Global Plan towards the Elimination of New HIV Infections among
Children by 2015 and Keeping Their Mothers Alive was launched to scale up efforts to …

Background Universal antiretroviral therapy (ART) for all pregnant/breastfeeding women
living with Human Immunodeficiency Virus (HIV), known as Prevention of mother-to child …

In a previous issue of the Southern African Journal of HIV Medicine, Pillay and Black
summarised the trade-offs of the safety of efavirenz use in pregnancy (Pillay P, Black V …

Background Option B+ marked a milestone in prevention of mother-to-child transmission
(PMTCT) of HIV by recommending lifelong antiretroviral therapy (ART) for all pregnant …

Background Prevention of mother-to-child transmission (PMTCT) across sub-Saharan Africa
has rapidly shifted towards Option B+, an approach in which all HIV+ pregnant and …

In 2010, WHO released guidelines for prevention of mother-to-child transmission (PMTCT) of
HIV1 that recom mended countries adopt one of two regimens: initiation of two antiretroviral …

Following the release in 2009 of the WHO PMTCT antiretroviral (ARV) rapid advice on
treating pregnant women and preventing infection in infants that recommended ARV options …

Since 2012, lifelong antiretroviral therapy for all HIV-positive pregnant women (“Option B+”)
is recommended by WHO for the prevention of mother-to-child transmission of HIV (PMTCT) …